Stay updated with breaking news from Fredd Lublin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say that's both a blessing and problem.
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th...
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences ...